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Abstract
Psoriasis is a common, chronic immune-mediated multifactorial skin disease. In its pathogenesis altered differ-
entiation and hyperproliferation of keratinocytes, dysregulation of immunological cell functions, together with 
abnormal angiogenesis are involved. Angiogenesis is defined as the formation of new blood vessels from the 
pre-existing vascular bed. This complex and multistep process is regulated by different factors among which 
vascular endothelial growth factor (VEGF) is considered to be the most important. The aim of this paper is 
a review of the current literature considering the role of vascular endothelial growth factor in psoriasis. Many 
studies have focused on the role of VEGF in psoriasis and revealed its increased serum and tissue levels which 
correlated with disease severity. Recent data indicate that VEGF is not only responsible for angiogenesis, but 
also regulates keratinocyte differentiation. Moreover, it has been suggested that vascular endothelial growth 
factor could be a link between psoriasis and its comorbidities. So far, there are single clinical cases that reported 
clearance of psoriasis after anti-VEGF therapy. Therefore, the VEGF pathway might be a potential new thera-
peutic alternative leading to improvement of psoriasis. However, further clinical studies are needed to evaluate 
the efficacy and safety of this therapy in psoriasis.
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Introduction
Psoriasis is a chronic immune-mediated multifactori-
al skin disease affecting 1–3% of the world’s population 
[1, 2]. Recent studies have improved our understanding 
of the immunopathological mechanisms of psoriasis and 
therefore facilitated its therapy [3]. Apart from dys-
regulation of immunological cell functions, the altered 
differentiation and hyperproliferation of keratinocytes 
together with abnormal angiogenesis are involved in 
the development of psoriasis [1, 2].
In psoriasis, the first pathological change is vascular 
proliferation, with the dermal papilla blood vessels 
being dilated, elongated and tortuous [2, 4]. Lympho-
cytic infiltrate and oedema are also present [4]. These 
changes appear before epidermal hyperplasia becomes 
apparent. Psoriatic plaques clear after these changes dis-
appear [5, 6]. Clinically, vascular proliferation manifests 
as the Auspitz’s sign [7]. Apart from the morphological 
changes described, there are also ultrastructural trans-
formations in the capillaries. As shown with the use of 
electron microscopy, features typical of venous capillar-
ies, e.g. basement membrane (single or multi-layered) 
or endothelial bridged fenestration, are displayed by 
capillary loops in psoriatic plaques, unlike healthy skin 
capillaries, which preserve features characteristic of ar-
terial vessels [5, 6]. Treatment results in the remodelling 
of the former into arterial type capillaries [6].
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Since angiogenesis defined as the formation of new 
blood vessels from the pre-existing vascular bed is a cru-
cial component of psoriasis pathogenesis, it is of special 
interest to identify factors responsible for angiogenesis 
control. Vascular endothelial growth factor (VEGF) is 
considered the main factor responsible for regulating 
angiogenesis. The VEGF superfamily includes VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental 
growth factor (PLGF). However, the term VEGF usually 
refers to VEGF-A, which is the main member of the 
VEGF superfamily [8, 9]. Different cell types can express 
VEGF, including monocytes/ macrophages, keratino-
cytes, fibroblasts, osteoblasts, astrocytes and tumour 
cells [10–12]. The main inducer of VEGF synthesis is 
low oxygen concentration [5]. An important role in the 
induction of VEGF expression is also played by different 
proinflammatory cytokines: interleukins 8 and 17A 
(IL-8, IL-17A), tumour necrosis factor alpha (TNF-a), 
some growth factors: basic fibroblast growth factor 
(bFGF), transforming growth factor-beta (TGF-β), 
and prostaglandins. Hypoglycaemia also increases its 
synthesis [5, 13–15]. 
VEGF exerts its biological function through its 
receptors. There are three VEGF receptors belonging 
to the kinase family: vascular endothelial growth factor 
receptor-1(VEGFR-1) , vascular endothelial growth 
factor receptor-2 (VEGFR-2) also called kinase insert 
domain-containing receptor (KDR) and vascular en-
dothelial growth factor receptor-3 (VEGFR-3). The 
first two types are expressed mainly by blood vascular 
endothelium; however, they were also identified on 
various cell types, including monocytes, macrophages, 
haematopoietic stem cells, platelets or vascular smooth 
muscle cells [16, 17], whereas VEGFR-3 expression is 
restricted to the lymphatic endothelium [17]. Apart 
from the receptors described above, VEGF can also 
bind to neuropilin-1 (NRP-1) and neuropilin-2 (NRP-2). 
It was demonstrated that NRP-1 binds VEGF-A and acts 
as co-receptor for VEGFR-2, which leads to enhance-
ment of VEGF signalling and function [18]. Herzog et 
al. [18] found that VEGF binding to NRP-1 has specific 
effects on endothelial cell signalling and is important for 
endothelial cell migration and angiogenesis mediated via 
complex formation between NRP-1 and KDR. It also 
increases signalling to focal adhesions, whereas NRP-2 
together with VEGFR-3 is involved in mediating VEGF-C 
signalling in lymphatic vessels [19]. 
VEGF exerts the most potent effect on endothe-
lial cells by stimulating their proliferation, migration 
and inhibiting endothelial cell apoptosis. Moreover, it 
increases vascular permeability and stimulates blood 
vessel dilation [20]. VEGF also acts as a chemoattractant 
for leukocytes, stimulates matrix metalloproteinase 
(MMP) synthesis and expression of adhesive mole-
cules, and regulates the function of dendritic cells and 
lymphocytes. Due to its multidirectional action, VEGF 
may be involved in different inflammatory processes, 
autoaggressive reactions or allergic reactions [21].
The aim of this paper is a review of the current 
literature considering the role of VEGF in psoriasis.
VEGF in psoriasis
Many studies have focused on the role of VEGF in 
psoriasis. It was demonstrated that VEGF transgenic 
mice had an increased density of tortuous cutaneous 
blood capillaries accompanied by elevated expression 
of VEGFR-1 and VEGFR-2 [22]. Then Xia et al. [23] ob-
served that an excess of VEGF in K14-VEGF transgenic 
mice can promote the development of a phenotype 
resembling human psoriasis, including elongated and en-
larged vessels in the dermal papillae, abnormal epider-
mal proliferation and differentiation with parakeratosis 
and hyperkeratosis found in skin biopsies. Interestingly, 
the psoriasis-like lesions occurred in mice older than 5 
months, which suggests that chronic overexpression of 
VEGF is required for the development of these lesions. 
Moreover, the authors demonstrated that the psoria-
sis-like phenotype can be normalized after VEGF block-
ade [23]. Following these observations, many studies 
were conducted to evaluate the role of human cutane-
ous VEGF in psoriasis. VEGF can be expressed by kerat-
inocytes; however, the level of this growth factor is low 
in normal epidermis and increases in skin diseases asso-
ciated with angiogenesis and chronic inflammation [24]. 
Sankar et al. [6] observed that VEGF expression levels 
in skin biopsies taken from psoriatic plaques were 
significantly higher compared to the healthy controls. 
Similar results were reported by other authors [25, 26]. 
Data considering the correlation between VEGF levels 
in skin biopsies and psoriasis area and severity index 
(PASI) are inconclusive. Some studies have demonstrat-
ed a significant correlation [6], whereas other studies 
reported none [27]. Simonetti et al. [25] observed that 
VEGF overexpression in psoriatic skin correlated with 
hypoxia-inducible factor-1 alpha (HIF-1α) and MMP-2 
expression, which indicates that VEGF could play an 
important role in the link between inflammation and 
angiogenesis. Rashed et al. [26] found increased VEGF 
expression in the epithelium and moderate expression 
within inflammatory infiltrate and vessels. They also re-
ported a significant positive correlation between VEGF, 
inducible nitric oxide synthase (iNOS) and survivin. Like 
VEGF, survivin and iNOS were expressed at significantly 
higher levels in psoriatic plaques in comparison with 
healthy controls. This confirms that VEGF promotes 
endothelial cell survival and new blood vessel formation, 
and thus may play an important role in the development 
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of psoriasis. Contrary to those studies, Liew at al. [27] 
found no significant correlation between VEGF-A lev-
els in skin biopsies taken from patients with psoriasis 
and healthy volunteers. Nevertheless, the authors 
observed that in psoriatic skin, the intensity of staining 
for VEGF-C was significantly higher in comparison to 
healthy controls. Moreover in patients with psoriasis 
nerve growth factor (NGF) was significantly expressed 
compared with healthy controls. According to the au-
thors, this might suggest a synergistic interplay between 
NGF and VEGF-C in psoriasis, and this interplay could 
be a potential new therapeutic target in psoriasis vul-
garis [27]. Therefore the role of VEGF-C in psoriasis 
was studied. Moustou et al. observed higher expression 
of VEGF-C and VEGF-D on lymphatic vessels within 
psoriatic plaques than in the non-psoriatic adjacent 
skin. While etanercept therapy decreased expression 
of VEGF-C and VEGF-D. These findings suggest the 
presence of lymphatic vessels remodelling in psoriasis. 
However, further studies are necessary to clarify its 
role in the development and recession of psoriasis [28].
As mentioned above, VEGF exerts its biological ac-
tion through its receptors. Man et al. [29] demonstrated 
the presence of VEGF receptors on keratinocytes in 
normal human epidermis. Later, the authors found 
that in normal healthy skin, VEGFR-1 and VEGFR-2 
were expressed only in the basal and suprabasal layer, 
whereas in patients with psoriasis those receptors 
were expressed in keratinocytes in all layers of the 
epidermis within psoriatic plaques and in all layers 
except the stratum corneum in perilesional and non-le-
sional keratinocytes. Analysis of VEGFR mRNA and 
protein levels of VEGFRs revealed the highest levels 
in lesional keratinocytes in comparison to perilesional, 
non-lesional or healthy skin. Considering the presence 
of VEGFRs in parakeratotic stratum corneum within 
psoriatic plaques, it was suggested that expression of 
those receptors may correlate with keratinocyte dif-
ferentiation [30]. Then in a recent study, it was demon-
strated that overexpression of VEGFR-2 in psoriatic 
epidermis is associated with upregulation of keratins 
(K): K6, K16, K17, typical for incomplete keratinocyte 
differentiation, and downregulation of K1 and K10, 
which are characteristic for complete terminal differ-
entiated keratinocytes [31]. Later the authors found 
that VEGF upregulates the expression of K6, K16 and 
K17 in normal human epidermal keratinocytes via the 
STAT3 (signal transducer and activator of transcription), 
ERK1/2 (extracellular regulated protein kinase 1/2) and 
p38 pathways, whereas the VEGF-induced decrease 
of K1 and K10 expression in normal human epidermal 
keratinocytes is due to activation of the ERK1/2 path-
way. This study casts a new light on the role of VEGF 
in psoriasis and demonstrates that VEGF may promote 
aberrant keratin expression resulting in the keratinocyte 
hyperproliferation typical for psoriasis [31]. 
Apart from local overexpression of VEGF, it was 
demonstrated that patients with psoriasis have in-
creased serum levels of VEGF and these levels correlat-
ed with PASI score [1, 32–34]. Moreover, serum VEGF 
concentrations correlated with psoriasis duration [34]. 
flisiak et al. [1] observed that elevated serum concen-
trations of VEGF decreased after topical therapy but 
remained higher than in healthy controls. Interestingly, 
the concentration of soluble vascular endothelial growth 
factor receptor-1 (sVEGFR-1) remained significantly 
higher than in a control group regardless of treatment. 
According to the authors, it cannot be excluded that 
elevated levels of sVEGFR-1 are required to bind VEGF 
and prevent further proangiogenic signal transduction 
[1]. Andrys et al. [35] reported a significant reduction 
of plasma VEGF levels after combined therapy with 
UVB and coal tar [35]. Contrary to those studies, Ak-
man et al. [36] found elevated plasma levels of VEGF 
in psoriatic patients in comparison to healthy controls, 
but the differences were not statistically significant. 
Moreover, VEGF levels decreased after PUVA therapy 
but increased after narrow band UVB (NB-UVB) and 
Re-PUVA. It cannot be excluded that changes in VEGF 
levels may result from increased epidermal proliferation 
after UVB exposure and individual response to sys-
temic retinoids due to the rebound phenomenon [37]. 
However, further studies are required to explain 
these findings. In another study, the association be-
tween serum VEGF levels and psoriasis severity was 
not confirmed [38]. Yamamoto et al. [39] reported 
elevated serum levels of VEGF in a patient with severe 
generalised pustular psoriasis accompanied by blister 
formation and its decrease with remission. According to 
the authors, observed blister formation resulted from 
systemic administration of steroids that exacerbated 
psoriasis and enhanced microvascular hyperpermea-
bility. It has been suggested that increased circulating 
plasma levels of VEGF in patients with severe psoriasis 
can induce hyperpermeability of renal vessels, leading 
to proteinuria [40] Increased VEGF levels were also 
observed in psoriatic arthritis and correlated with CRP 
and disease duration [41].
Genetic studies have provided novel data regard-
ing the role of VEGF in psoriasis. The VEGF gene is 
located on 6p21.3 near the PSORS1 chromosomal 
locus for psoriasis susceptibility [7, 42]. Further studies 
demonstrated that two groups of psoriatic patients can 
be distinguished on the basis of their VEGF genotype: 
patients with “low and high VEGF production” [43]. Pa-
tients with high VEGF production are characterized by 
early psoriasis onset and a severe disease course [44]. 
Therefore, it has been suggested that individuals 
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with a high VEGF production may develop a “proan-
giogenic” psoriasis phenotype, which has therapeutic 
implications [7].
Since more than 250 aberrantly expressed MircroR-
NAs (miRNAs) in psoriasis were identified, many studies 
focused on its role in this disease [45, 46]. A possible link 
between miRNAs and VEGF expression was also stud-
ied [46–48]. Li et al. [46] observed that expression of 
hif-1α and VEGF-A were down-regulated by miR-150 
overexpression while promoted by miR-150 inhibition 
in HaCaT cells and primary adult human keratinocytes 
(hKcs). Xu et al. [49] suggested that miR203 expres-
sion may be upregulated by IL-17 stimulation, and 
miR203 is a positive regulator of IL-17-induced VEGF 
secretion. Evaluation of the role of specific miRNAs in 
psoriasis and regulation of angiogenesis seems to be 
important, but more studies are necessary. 
It is well known that psoriasis is associated with 
many comorbidities, including diabetes, lipid abnormali-
ties, obesity and metabolic syndrome. Patients with pso-
riasis have an increased risk of cardiovascular diseases 
such as atherosclerosis [7]. Significantly, angiogenesis 
plays an important role in the development of both 
psoriasis and atherosclerosis. In psoriasis, local levels 
of VEGF in psoriatic plaques are elevated and correlate 
with disease severity; the same is true for VEGF levels 
within the atherosclerotic plaque. Likewise, the “high 
VEGF-producing” genotype (+405CC) in psoriasis this 
genotype is associated with a poor prognosis in patients 
with chronic heart failure [7]. In both diseases, at the 
beginning, local hypoxia triggers the release of hypox-
ia-inducible factor 1 (HIF-1) with a further expression of 
VEGF which leads to the formation of new vessels and 
promotes lymphocyte migration via increased expres-
sion of adhesive molecules [7, 22]. Moreover, oxidized 
phospholipids known as crucial factors in the develop-
ment of atherosclerotic plaques can enhance VEGF ex-
pression in keratinocytes, which suggests their potential 
role in psoriasis [7]. These data emphasize that VEGF 
is not only involved in angiogenesis and keratinocyte 
differentiation but could also be a link between psoriasis 
and its comorbidities. It has been suggested that en-
hanced expression of VEGF secondary to one of those 
diseases may influence or exacerbate the other [7]. 
Therefore, VEGF or its receptors could be a potent 
target for future therapies.
VEGF-targeted therapy in psoriasis
VEGF inhibitors are currently licensed for the treat-
ment of eye diseases or malignancies. Most of them 
target the VEGF pathway either by direct inhibition of 
VEGF protein, indirectly by inhibiting tyrosine kinase 
signalling and by blocking the VEGF receptor, or by 
preventing the binding of VEGF to its receptor [37, 
49]. So far there are single clinical cases that reported 
clearance of psoriasis after anti-VEGF therapy. Akman et 
al. [50] reported complete remission of psoriasis after 
treatment with a monoclonal antibody against VEGF 
(bevacizumab) in a 60-year old man with metastatic 
colon cancer and long-lasting severe psoriasis. Later, 
Datta-Mitra et al. [51] reported complete remission 
of both psoriasis and psoriatic arthritis in a 65-year old 
male patient with metastatic renal cell carcinoma who 
received bevacizumab. Importantly, at the beginning, 
the patient received combined therapy with bevaci-
zumab and interferon-alpha, which led to significant 
improvement of both psoriasis and psoriatic arthritis 
after 3 months. However, due to development of pro-
teinuria, he was switched to treatment with tyrosine 
kinase inhibitors, during which his serum creatinine 
levels increased and a relapse of both psoriasis and 
psoriatic arthritis was observed. After re-initiation of 
monotherapy with bevacizumab, tumour stabilization, 
as well as, remission of psoriasis and psoriatic arthritis 
was achieved [51]. Contrary to the previous study, 
other authors observed remission of psoriasis during 
treatment with tyrosine kinase inhibitors [52, 53]. 
Recently, it has been demonstrated in an imiquimod-
induced mouse model of psoriasis that topical sunitinib 
can reduce imiquimod-induced psoriasis-like inflamma-
tion [54]. As mentioned above, targeting VEGF signalling 
might be a promising therapeutic option. However, it 
cannot be excluded that an additional factor might also 
have a beneficial effect on psoriasis during this oncologic 
therapy [37]. One of the most important triggering 
factors in psoriasis is stress. Therefore, stabilisation of 
cancer during anti-VEGF treatment may reduce stress 
and improve the course of psoriasis [37]. A further 
aspect that has to be considered during anti-VEGF 
therapy in psoriatic patients are side effects such as 
hypertension, left ventricular dysfunction or gastroin-
testinal perforation. Cardiovascular complications are of 
special interest since psoriatic patients have increased 
cardiovascular risk [37]. Apart from novel experimental 
therapies, there is evidence that traditional medications 
also affect angiogenesis. It was found that inhibiting the 
activity of transcription factors of the nuclear factor of 
activated T cells family by cyclosporine A decreases mi-
gration of primary endothelial cells and VEGF-induced 
angiogenesis [49]. Therapy with TNF inhibitors also 
reduces VEGF expression, leading to a decreased blood 
supply [49].
To sum up, a growing body of evidence suggests an 
important role of VEGF and its receptors in psoriasis. 
Recent data indicate that VEGF is not only responsi-
ble for angiogenesis, but also regulates keratinocyte 
differentiation. The results of many studies indicate 
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that targeting the VEGF pathway might be a potential 
new therapeutic alternative leading to improvement of 
psoriasis. However, further clinical studies are needed 
to evaluate the efficacy and safety of this therapy in 
psoriasis.
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